New phosphate granules aim to fix dangerous mineral deficiency in hospital patients
NCT ID NCT07233889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a phosphate supplement in granule form can safely raise low blood phosphate levels in 60 ICU patients. Participants take the granules daily for up to 14 days, with doses adjusted based on how low their phosphate is. Researchers will check blood levels daily and watch for stomach issues.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sodium dihydrogen phosphate and disodium hydrogen phosphate granules
- What this could lead to
- If successful, this could provide a simple, safe way to correct low phosphate levels in hospitalized patients, potentially reducing complications.
- What could go wrong
- This is a small, early-stage trial with only 60 participants. The treatment may not work as expected or could cause gastrointestinal side effects. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Aged 18-80 years (inclusive), regardless of gender; 2. ICU inpatients with a serum phosphate concentration \<0.80 mmol/L, and for whom the clinician determines phosphate supplementation is required; 3. Ability to receive enteral nutrition, with a daily enteral caloric intake ≥10 kcal/kg/day; 4. The subject or their legal guardian fully understands the purpose and significance of this trial, voluntarily agrees to participate, provides written informed consent, and is willing to strictly adhere to the clinical study protocol and complete the study. Exclusion Criteria: 1. Pregnant and lactating women; 2. Patients with contraindications for enteral administration, such as acute upper gastrointestinal bleeding, mechanical intestinal obstruction, severe acute pancreatitis, digestive tract fistula, gastrointestinal dysfunction, intra-abdominal hypertension, enteral feeding intolerance, or continuous gastrointestinal decompression; 3. Expected ICU stay ≤96 hours; 4. Known allergy to any component of the investigational drug or drugs with a similar chemical structure; 5. Severe renal impairment: estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m²; 6. Subjects with hyperthyroidism requiring clinical intervention; 7. Subjects requiring sodium restriction; 8. Other conditions deemed by the investigator as unsuitable for inclusion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypophosphatemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.